Moreover, treatment with R428, a tyrosine kinase inhibitor targeting Axl receptor tyrosine kinase indicated different effectiveness in inhibiting cancer cell proliferation both in cell lines and mouse model, which was due to differences in hyperphosphorylation of Axl on Tyr634, Tyr702 and Tyr703 across the three metastatic cell types. This evidence concerns the gene AXL and cancer.